FDA WARNING_LETTER - Neoteric Cosmetics, Incorporated/Scott’s Liquid Gold, Inc. - April 19, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA issued a Warning Letter to Ms. Pedrazzini concerning her subsidiary, Neoteric Cosmetics, Inc., for distributing ALPHA® SKIN CARE Dual Action Fade Cream. This product is an unapproved new drug and misbranded under the Federal Food, Drug & Cosmetic Act (FD&C Act).
The product is deemed a drug due to its intended use for skin bleaching, with claims like "Dual Action Skin Lightener," "Helps to fade the dark spots," and containing "2% Hydroquinone, a proven skin lightener." These claims, found on the product label and website, indicate its intent to affect body structure/function and treat/mitigate disease.
As a skin bleaching drug, it falls under section 505G(a)(4) of the FD&C Act, which deems it not generally recognized as safe and effective (GRASE) per a 2006 proposed rule. Consequently, it is considered a new drug requiring an approved application under section 505 of the FD&C Act since September 23, 2020. No such approval exists for ALPHA® SKIN CARE Dual Action Fade Cream, violating section 505(a) and 301(d).
Furthermore, the product is misbranded under section 502(ee) and 301(a) because it is a nonprescription drug subject to section 505G but lacks an approved application
- Inspection Date
- April 19, 2022
- Product Type
- Drugs
ID · f9a5024b-02ab-469b-8cb7-ab3b8b2bb439
Full citation text and observation details available on the Dashboard.